Drappa Jorn 4

What Happened

• Drappa Jorn, Chief Medical Officer of Alumis Inc. (ALMS), exercised stock options on May 22, 2026, acquiring a total of 26,852 shares (11,317 and 15,535 shares). He paid $8.84 per share for 11,317 shares ($100,042) and $5.06 per share for 15,535 shares ($78,607), for a combined cash outlay of $178,649. The filing also reports the corresponding derivative option interests as disposed at $0, reflecting conversion/termination of the options upon exercise.
• This is an acquisition (exercise) rather than a sale; Jorn paid cash to convert options into common shares and did not report an immediate sale.

Key Details

• Transaction date: May 22, 2026.
• Prices and amounts: 11,317 shares @ $8.84 = $100,042; 15,535 shares @ $5.06 = $78,607; total 26,852 shares for $178,649.
• Disposition entries at $0 reflect the canceled/converted derivative option instruments (reported as code M).
• Shares owned after the transaction: not specified in the Form 4 provided.
• Filing date: May 27, 2026 — filed within the SEC Form 4 deadline (timely).
• Notable footnotes:
  • F1: Reporting person also holds shares acquired under the Issuer’s 2024 Employee Stock Purchase Plan (1,037 shares on Nov 20, 2025 and 3,000 shares on May 20, 2026).
  • F2/F3: The exercised options are subject to standard vesting schedules: one tranche vested 25% on Aug 22, 2023 with the remainder monthly over 36 months; another tranche vested 25% on Feb 18, 2026 with the remainder monthly over 36 months, subject to continued service and possible acceleration.

Context

• For retail investors: exercising options is a common way insiders convert vested derivative awards into shares. Because Jorn paid cash to acquire shares and did not immediately sell them, this transaction increases his direct equity stake in the company rather than representing a liquidity event.
• These filings are factual records of ownership changes and do not by themselves indicate the insider’s view of the company’s future performance.